DB05873InvestigationalSmall molecule
AVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).
- Mechanism
- Curator reviewed
AVI-4020 has rapid response therapeutics that plays a significant role in the future of antiviral therapeutics, especially in combating emerging infectious diseases that threaten public health or in combating bioterrorism.
- Primary indication
- Investigated for use/treatment in infectious and parasitic disease (unspecified) and viral infection.Curator reviewed
- Code names
- AVI-4020
What you can answer from here — as of April 02, 2025
Which companies are running trials of AVI-4020, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account